ACET Adicet Bio, Inc.
Nasdaq · SEC CIK 1720580 · EDGAR
- Bought, last 12 months
- $6.60M 2 purchases by 2 insiders
- Sold, last 12 months
- $674.8K 1 sales by 1 insiders
- Filings on record
- 157 since 2021-10-05, latest 2026-08-07 16:01
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% | $5.00M | $674.8K |
| RA CAPITAL MANAGEMENT, L.P. | 10% | $1.60M | — |
| Aftab Blake | CSO | — | — |
| Healey Don | CTO | — | — |
| Harvey Brian Nicholas | CFO | — | — |
| Schor Chen | Pres, CEO, Dir | — | — |
Transactions 127
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-02-16 | 2022-02-14 | ACET | Healey Don | CTO | A - Grant | $0.00 | +16.0K | 58.5K | +38% | $0 | |
| 2022-02-16 | 2022-02-14 | ACET | Harvey Brian Nicholas | CFO | A - Grant | $0.00 | +16.0K | 59.3K | +37% | $0 | |
| 2022-02-16 | 2022-02-14 | ACET | Harvey Brian Nicholas | CFO | F - Tax | $14.27 | -4,696 | 54.6K | -8% | -$67.0K | |
| 2022-02-16 | 2022-02-14 | ACET | Aftab Blake | CSO | F - Tax | $14.27 | -5,533 | 52.9K | -9% | -$79.0K | |
| 2022-02-16 | 2022-02-14 | ACET | Aftab Blake | CSO | A - Grant | $0.00 | +16.0K | 58.4K | +38% | $0 | |
| 2022-02-16 | 2022-02-14 | ACET | Galimi Francesco | SVP, Chief Medical Off | F - Tax | $14.27 | -5,533 | 59.9K | -8% | -$79.0K | |
| 2022-02-16 | 2022-02-14 | ACET | Galimi Francesco | SVP, Chief Medical Off | A - Grant | $0.00 | +16.0K | 65.5K | +32% | $0 | |
| MI | 2022-02-14 | 2022-01-03+ | ACET | Jakobovits Aya | Dir | S - Sale | $16.51 | -24.0K | 366.3K | -6% | -$396.1K |
| 2022-02-01 | 2022-01-28 | ACET | Galimi Francesco | SVP, Chief Medical Off | F - Tax | $11.69 | -5,533 | 49.5K | -10% | -$64.7K | |
| 2022-02-01 | 2022-01-28 | ACET | Galimi Francesco | SVP, Chief Medical Off | A - Grant | $0.00 | +16.0K | 55.0K | +41% | $0 | |
| 2022-02-01 | 2022-01-28 | ACET | Schor Chen | Pres, CEO, Dir | F - Tax | $11.69 | -21.3K | 122.7K | -15% | -$248.9K | |
| 2022-02-01 | 2022-01-28 | ACET | Schor Chen | Pres, CEO, Dir | A - Grant | $0.00 | +48.0K | 144.0K | +50% | $0 | |
| 2022-02-01 | 2022-01-28 | ACET | Healey Don | CTO | A - Grant | $0.00 | +16.0K | 48.0K | +50% | $0 | |
| 2022-02-01 | 2022-01-28 | ACET | Healey Don | CTO | F - Tax | $11.69 | -5,533 | 42.5K | -12% | -$64.7K | |
| 2022-02-01 | 2022-01-28 | ACET | Harvey Brian Nicholas | CFO | A - Grant | $0.00 | +16.0K | 48.0K | +50% | $0 | |
| 2022-02-01 | 2022-01-28 | ACET | Harvey Brian Nicholas | CFO | F - Tax | $11.69 | -4,696 | 43.3K | -10% | -$54.9K | |
| 2022-02-01 | 2022-01-28 | ACET | Aftab Blake | CSO | F - Tax | $11.69 | -5,564 | 42.4K | -12% | -$65.0K | |
| 2022-02-01 | 2022-01-28 | ACET | Aftab Blake | CSO | A - Grant | $0.00 | +16.0K | 48.0K | +50% | $0 | |
| I | 2021-12-14 | 2021-12-10 | ACET | GORDON CARL L | Dir, 10% | A - Grant | $14.00 | +214.3K | 242.3K | +765% | +$3.00M |
| I | 2021-12-14 | 2021-12-10 | ACET | OrbiMed Israel GP II, L.P. | Dir, 10% | A - Grant | $14.00 | +214.3K | 242.3K | +765% | +$3.00M |
| AI | 2021-12-13 | 2021-12-08 | ACET | Sinclair Andrew | Dir | P - Purchase | $14.00 | +500.0K | 2.12M | +31% | +$7.00M |
| I | 2021-12-10 | 2021-12-08 | ACET | Sinclair Andrew | Dir | P - Purchase | $14.00 | +500.0K | 2.14M | +30% | +$7.00M |
| D | 2021-10-13 | 2021-10-12 | ACET | Aftab Blake | CSO | A - Grant | $0.00 | +80.0K | 80.0K | New | $0 |
| 2021-10-05 | 2021-10-01 | ACET | Schor Chen | Pres, CEO, Dir | A - Grant | $0.00 | +240.0K | 240.0K | New | $0 | |
| 2021-10-05 | 2021-10-01 | ACET | Harvey Brian Nicholas | CFO | A - Grant | $0.00 | +80.0K | 80.0K | New | $0 | |
| 2021-10-05 | 2021-10-01 | ACET | Healey Don | CTO | A - Grant | $0.00 | +80.0K | 80.0K | New | $0 | |
| 2021-10-05 | 2021-10-01 | ACET | Galimi Francesco | SVP, Chief Medical Off | A - Grant | $0.00 | +80.0K | 87.0K | +1,146% | $0 |
Purchase Sale Sale after option exercise All abbreviations